Genezen Strengthens Leadership with New Board Appointments
Source:

Genezen Laboratories, Inc.

June 10, 2021

Following major growth, Genezen Laboratories Inc, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has announced the appointment of three board members: Iain Baird, Diana Caldwell and Tedd Green.

The expansion of the team comes as Genezen works to meet the increasing demand of the cell and gene therapy sector and ramp up its service offering in the manufacturing of viral vectors, including early phase process development, vector production, and analytical testing services.

Bill Vincent, Chairman and CEO of Genezen said: “I am very pleased to be welcoming Iain, Diana and Tedd to the Genezen team.

“Their skills and experience will be instrumental in helping us to build on our deep expertise in the lentiviral vector platform. They will all play a pivotal role in developing and delivering a range of differentiated services as we help customers bring life-changing therapies to market.”

Iain Baird:

Iain brings over 30 years of sector experience to Genezen, previously leading the CMC development of vaccines as well as designing and project managing biologic and CDMO facility builds in the cell and gene space. With extensive knowledge in quality and compliance, he has worked as an advisor to founders and CEOs at companies including Brammer Bio, OSO BioPharmaceuticals, and CANbridge Life Sciences.

Diana Caldwell:

Diana, current President, CEO and co-founder of Amplified Sciences, a start-up in-vitro diagnostics company that aims to detect and prevent disease, brings 25 years of entrepreneurial and life science experience to Genezen. After a career in marketing at Eli Lilly, she founded and was CEO of Pearl Pathways in the regulatory and quality space and has supported a number of large and small biotech companies in driving growth while adding value for customers and patients.

Tedd Green:

Tedd has over 15 years’ experience driving the success of CDMOs in the biopharmaceutical industry including roles as President of Cook Pharmica and Senior Vice President of Catalent Biologics.  He co-founded and is currently COO at INCOG BioPharma Services. Tedd’s extensive leadership, finance and operational experience will be invaluable to Genzen’s ambitious growth plans.

-ENDS-

For further information, images and interview opportunities, please contact Lara Lovenbury at ramarketing: lara@ramarketingpr.com | +44 (0)773 268 1275 | ramarketingpr.com | Twitter: @ramarketingpr | Facebook: /ramarketingpr | Linkedin: /ramarketing

About Genezen Laboratories, Inc.

Founded in Indianapolis in 2014, Genezen Laboratories is focused on supporting the demands of the current and future gene and cell therapy manufacturing market worldwide— making viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen offers early-phase process development, GMP vector production, and analytical testing services, building on the company’s expansive knowledge and experience in the industry and working with the nation’s leading institutions. For more information, or to learn more about services offered in Genezen’s new cGMP facility, please visit www.genezenlabs.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com.

Post a Comment

You must be logged in to post a Comment.

FEEDBACK